Phreesia (NYSE:PHR) Expected to Announce Quarterly Sales of $29.46 Million

Equities analysts expect Phreesia (NYSE:PHR) to report sales of $29.46 million for the current quarter, Zacks reports. Four analysts have made estimates for Phreesia’s earnings, with the highest sales estimate coming in at $29.60 million and the lowest estimate coming in at $29.30 million. The company is expected to issue its next earnings report after the market closes on Monday, December 9th.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

On average, analysts expect that Phreesia will report full-year sales of $118.86 million for the current year, with estimates ranging from $118.70 million to $118.96 million. For the next financial year, analysts anticipate that the business will post sales of $142.28 million, with estimates ranging from $141.70 million to $142.76 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Phreesia.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Monday, September 9th. The company reported ($10.42) EPS for the quarter, missing the consensus estimate of ($0.12) by ($10.30). The company had revenue of $30.82 million during the quarter, compared to the consensus estimate of $30.05 million.

PHR has been the topic of several recent analyst reports. ValuEngine cut Phreesia from a “buy” rating to a “hold” rating in a research report on Thursday, October 31st. Piper Jaffray Companies set a $33.00 price objective on Phreesia and gave the company a “buy” rating in a research report on Tuesday, September 10th. Robert W. Baird initiated coverage on Phreesia in a research report on Thursday, October 10th. They set an “outperform” rating and a $31.00 price objective on the stock. Wells Fargo & Co initiated coverage on Phreesia in a research report on Monday, August 12th. They set an “outperform” rating and a $23.00 price objective on the stock. Finally, Zacks Investment Research cut Phreesia from a “hold” rating to a “sell” rating in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Phreesia has a consensus rating of “Buy” and a consensus price target of $30.60.

A number of hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. bought a new position in Phreesia in the third quarter valued at about $47,000. Tower Research Capital LLC TRC bought a new position in Phreesia in the third quarter valued at about $68,000. Rhumbline Advisers bought a new position in Phreesia in the third quarter valued at about $208,000. Dean Capital Investments Management LLC bought a new position in Phreesia in the third quarter valued at about $580,000. Finally, Emerald Advisers LLC bought a new position in Phreesia in the third quarter valued at about $1,036,000. 10.73% of the stock is currently owned by institutional investors.

Shares of Phreesia stock traded up $0.07 during trading on Friday, hitting $28.95. 168,108 shares of the company’s stock traded hands, compared to its average volume of 255,427. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.52 and a quick ratio of 3.52. Phreesia has a 1 year low of $22.05 and a 1 year high of $31.00. The stock has a 50-day simple moving average of $27.83.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.

Recommended Story: Earnings Reports

Get a free copy of the Zacks research report on Phreesia (PHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *

*